Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

NCT02834013 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02834013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02834013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 30, 2017
Completion date
June 1, 2027
Enrollment
798 (actual)
Sites
1,007

Conditions

As the registry lists them; a condition with its own page is linked.

acinar cell carcinoma, adenoid cystic carcinoma, adrenal cortical carcinoma, adrenal gland pheochromocytoma, anal canal neuroendocrine carcinoma, anal canal undifferentiated carcinoma, angiosarcoma, apocrine neoplasm, appendix mucinous adenocarcinoma, bartholin gland transitional cell carcinoma, basal cell carcinoma, bladder adenocarcinoma, breast metaplastic carcinoma, cervical adenocarcinoma, cholangiocarcinoma, chordoma, colorectal squamous cell carcinoma, desmoid fibromatosis, endometrial transitional cell carcinoma, endometrioid adenocarcinoma, esophageal neuroendocrine carcinoma, esophageal undifferentiated carcinoma, extrahepatic bile duct carcinoma, extramammary paget disease, fallopian tube adenocarcinoma, fallopian tube transitional cell carcinoma, fibromyxoid tumor, gallbladder carcinoma, gastric neuroendocrine carcinoma, gastric squamous cell carcinoma, gastric undifferentiated carcinoma, gastrointestinal stromal tumor, gestational trophoblastic tumor, giant cell carcinoma, human papillomavirus-independent cervical adenocarcinoma, clear cell-type, intestinal neuroendocrine carcinoma, intrahepatic cholangiocarcinoma, lung neuroendocrine tumor, lung sarcomatoid carcinoma, major salivary gland carcinoma, malignant neoplasm of unknown primary, malignant odontogenic neoplasm, malignant peripheral nerve sheath tumor, malignant solid neoplasm, malignant testicular sex cord-stromal tumor, metastatic pituitary neuroendocrine tumor, minimally invasive lung adenocarcinoma, mixed mesodermal (mullerian) tumor, mucinous adenocarcinoma, mucinous cystadenocarcinoma, nasal cavity adenocarcinoma, nasal cavity carcinoma, nasopharyngeal carcinoma, nasopharyngeal low grade papillary adenocarcinoma, nasopharyngeal undifferentiated carcinoma, oral cavity carcinoma, oropharyngeal undifferentiated carcinoma, ovarian adenocarcinoma, ovarian germ cell tumor, ovarian mucinous adenocarcinoma, ovarian squamous cell carcinoma, ovarian transitional cell carcinoma, pancreatic acinar cell carcinoma, pancreatic neuroendocrine carcinoma, paraganglioma, paranasal sinus adenocarcinoma, paranasal sinus carcinoma, parathyroid gland carcinoma, pecoma, penile squamous cell carcinoma, peritoneal mesothelial neoplasm, placental choriocarcinoma, primary peritoneal high grade serous adenocarcinoma, pseudomyxoma peritonei, rare disorder, scrotal squamous cell carcinoma, seminal vesicle adenocarcinoma, seminoma, serous cystadenocarcinoma, small intestinal adenocarcinoma, small intestinal squamous cell carcinoma, spindle cell neoplasm, teratoma with somatic-type malignancy, testicular non-seminomatous germ cell tumor, thyroid gland carcinoma, tracheal carcinoma, transitional cell carcinoma, ureter adenocarcinoma, ureter squamous cell carcinoma, urethral adenocarcinoma, urethral squamous cell carcinoma, vaginal adenocarcinoma, vaginal squamous cell carcinoma, not otherwise specified, vulvar carcinoma